Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors-Reference-Cited by-同舟云学术

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors

Published:2020-01-01 Issue:1 Volume:6 Page:100
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Heinhuis Kimberley M.¹,Carlino Matteo²,Joerger Markus³,Di Nicola Massimo⁴,Meniawy Tarek⁵,Rottey Sylvie⁶,Moreno Victor⁷,Gazzah Anas⁸,Delord Jean-Pierre⁹,Paz-Ares Luis¹⁰,Britschgi Christian¹¹,Schilder Russell J.¹²,O’Byrne Kenneth¹³,Curigliano Giuseppe¹⁴,Romano Emanuela¹⁵,Patah Poliana¹⁶,Wang Rui¹⁶,Liu Yali¹⁶,Bajaj Gaurav¹⁶,Siu Lillian L.¹⁷

Affiliation:

1. Division of Pharmacology, The Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, the Netherlands

2. Department of Medical Oncology, Crown Princess Mary Cancer Centre Westmead Hospital, Westmead, Australia

3. Department of Internal Medicine, Clinic for Medical Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland

4. Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori Milano, Milano, Italy

5. Linear Clinical Research Ltd, Nedlands, Australia

6. Department of Medical Oncology, Universitair Ziekenhuis Ghent, Ghent, Belgium

7. South Texas Accelerated Research Therapeutics Madrid-Fundacion Jimenez Diaz, Fundacion Jimenez Diaz Hospital, Madrid, Spain

8. Drug Development Department, Gustave Roussy, Villejuif, France

9. Medical Oncology Departement, Institut Claudius Regaud and Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

10. Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

11. Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland

12. Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

13. Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia

14. New Drugs Development Division for Innovative Therapies, University of Milano and Istituto Europeo Di Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Milano, Italy

15. Department of Oncology, Center of Cancer Immunotherapy, U932, Institut Curie, Paris, France

16. Bristol-Myers Squibb, Princeton, New Jersey

17. Bras and Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2754745/jamaoncology_heinhuis_2019_oi_190078.pdf

Reference37 articles.

1. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.;Schaer;J Immunother Cancer,2014

2. Nivolumab for recurrent squamous-cell carcinoma of the head and neck.;Ferris;N Engl J Med,2016